With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth ...

Gene expression testing helps determine chemotherapy needs for hormone receptor-positive breast cancer, optimizing treatment ...

Investment analysts at Lifesci Capital decreased their FY2025 earnings per share (EPS) estimates for Olema Pharmaceuticals in ...

The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...

Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026Pivotal Phase 3 OPERA-02 trial of palazestrant in combi ...

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They ...

More and more people are talking about Novartis over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $112.13? Only time will tell. The information below will give you a ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the ...